Drug
Carrelizumab
Carrelizumab is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(20%)
Phase Distribution
Ph phase_2
3
60%
Ph not_applicable
2
40%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
N/ANon-phased studies
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Other(3)
Detailed Status
unknown3
Recruiting1
Enrolling by invitation1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 23 (60.0%)
N/A2 (40.0%)
Trials by Status
recruiting120%
enrolling_by_invitation120%
unknown360%
Recent Activity
1 active trials
Showing 5 of 5
recruitingphase_2
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
NCT05594095
unknownphase_2
A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma
NCT05576272
enrolling_by_invitationnot_applicable
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
NCT06048926
unknownnot_applicable
Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma
NCT05697237
unknownphase_2
Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
NCT04943029
Clinical Trials (5)
Showing 5 of 5 trials
NCT05594095Phase 2
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
NCT05576272Phase 2
A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma
NCT06048926Not Applicable
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
NCT05697237Not Applicable
Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma
NCT04943029Phase 2
Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5